What drugs does IMMEDICA PHARMA AB make?

IMMEDICA PHARMA AB has 1 FDA-approved drugs including LOARGYS.

What therapeutic areas does IMMEDICA PHARMA AB focus on?

IMMEDICA PHARMA AB focuses primarily on Oncology.

← Back

Data updated: Sep 20, 2026

IMMEDICA PHARMA AB

Biotech

Oncology

IMMEDICA PHARMA AB is a biotechnology company focused on Oncology.

2026

Since

Drugs

Trials

New Drugs (2yr)

IMMEDICA PHARMA AB's Key Drugs

IMMEDICA PHARMA AB's core commercial portfolio centers on LOARGYS, spanning Oncology — its most strategically important drugs approved in the last 15 years.

LOARGYS

Oncology

Approved 2026

IMMEDICA PHARMA AB's Recent FDA Approvals

IMMEDICA PHARMA AB secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LOARGYS BLA

2026-02-23

pegzilarginase-nbln

1 INDICATIONS AND USAGE LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. ( 1 ) This indication is approved under accelerated approval based on reduction of plasma arginine. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )

IMMEDICA PHARMA AB's Therapeutic Areas

IMMEDICA PHARMA AB's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%

0 drugs Phase 1: 2

IMMEDICA PHARMA AB's Top Competitors

IMMEDICA PHARMA AB's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.